Love Douglas purchased $100K of ANNX

Love Douglas (PRESIDENT AND CEO) purchased 26,065 shares of Annexon, Inc. (ANNX) at $3.83 on 2026-09-24.

Original reporting
SEC EDGAR · Love Douglas
Published Sep 25, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANNX
Bullish
medium confidence
Mentioned
$ANNX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANNXBullishMed
01

Why it matters

The purchase may signal confidence from leadership, prompting short-term buying interest.

02

Market read

CEO's $100K share purchase could influence Annexon's stock momentum.

03

What to watch

Potential upcoming product launches or contracts not disclosed yet.

Relevance 4/10Novelty 7/10Timing: filing posted 2026-09-25

Background

Form 4 filing discloses insider transactions; such filings are primary sources of new information.

Company-level read

Ticker impact

$ANNXBullishMedium confidence
Context

CEO Love Douglas bought 26,065 shares for $99,828.95, increasing his stake to 390,476 shares.

Expected impact

Possible short-term price uptick as market views purchase favorably.

Evidence & confidence

CEO acquisition of ~100k USD is material for a micro‑cap, indicating insider belief in future performance.

Market effects

Minimal; reflects confidence in Annexon's cybersecurity services sector.

Limited to US investors tracking insider activity.

Low; no broader market effect.

Counterpoint

Insider buying could be a window dressing move, not a genuine signal.

Key entities

  • Annexon, Inc.

    Cybersecurity firm listed on NASDAQ.

  • Love Douglas

    President and CEO of Annexon.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANNXHigh

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

$ANNXMed

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in G

$ANNXMed

H.C. Wainwright raises Annexon stock price target on GBS approval prospects

H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.

$ANNXMed

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.